Zongertinib (BI1810631), an irreversible HER2 TKI spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers

被引：0
|
作者：
Neumueller, R. [1 ]
Wilding, B. [1 ]
Augsten, M. [1 ]
Baum, A. [1 ]
Chylinski, K. [1 ]
Waizenegger, I. [1 ]
Woelflingseder, L. [1 ]
Solca, F. [1 ]
Kraut, N. [1 ]
机构：
[1] Boehringer Ingelheim RCV, Oncol Res, Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB124
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 29 条
  • [1] Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
    Wilding, Birgit
    Woelflingseder, Lydia
    Baum, Anke
    Chylinski, Krzysztof
    Vainorius, Gintautas
    Gibson, Neil
    Waizenegger, Irene C.
    Gerlach, Daniel
    Augsten, Martin
    Spreitzer, Fiona
    Shirai, Yukina
    Ikegami, Masachika
    Tilandyova, Sylvia
    Scharn, Dirk
    Pearson, Mark A.
    Popow, Johannes
    Obenauf, Anna C.
    Yamamoto, Noboru
    Kondo, Shunsuke
    Opdam, Frans L.
    Bruining, Annemarie
    Kohsaka, Shinji
    Kraut, Norbert
    Heymach, John V.
    Solca, Flavio
    Neumueller, Ralph A.
    CANCER DISCOVERY, 2025, 15 (01) : 119 - 138
  • [2] Phase Ia/Ib trial of the HER2 tyrosine kinase inhibitor zongertinib (BI 1810631) in patients with HER2-driven solid tumors: Focus on Asian patients
    Yoh, K.
    Opdam, F.
    Barve, M.
    Tu, H.
    Wu, Y-L.
    Berz, D.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Heymach, J.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1637 - S1638
  • [3] A potent and highly selective irreversible HER2 inhibitor for treating HER2-driven cancers
    Zhao, Chunmei
    Kulyk, Lana
    Botrous, Iriny
    Chen, Kelly
    Zhao, Chang
    Banisadr, Afsheen
    Anderson, Mary L.
    Manby, Fred
    Miller, Tom
    Zhang, Chao
    Gomez, Laurent
    Huang, Zhongdong
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Beamion LUNG-1, a Phase Ia/Ib trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2-driven tumors: outcomes according to HER2 aberration type
    Berz, D.
    Heymach, J.
    Opdam, F.
    Barve, M.
    Tu, H.
    Wu, Y.
    Mueller, A. M.
    Schroeter, L.
    Sadrolhefazi, B.
    Yoh, K.
    Yamamoto, N.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162 : S127 - S127
  • [5] Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations
    Yamamoto, N.
    Opdam, F.
    Barve, M.
    Tu, H. -Y.
    Wu, Y. -L.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S147 - S147
  • [6] A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Wu, Y. L.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S1 - S1
  • [7] Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors
    Heymach, John
    Yamamoto, Noboru
    Opdam, Frans
    Barve, Minal
    Tu, Hai-Yan
    Wu, Yi-Long
    Schroeter, Lukas
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Berz, David
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E1 - E1
  • [8] Updated data from the phase I Beamion Lung 1 trial of BI 1810631, a HER2 TKI, in patients (pts) with advanced solid tumours with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Tu, H-Y.
    Wu, Y-L.
    Gibson, N. J.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S63 - S64
  • [9] HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study
    Heymach, John V.
    Opdam, Frans
    Barve, Minal
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Schroeter, Lukas
    Botilde, Yanick
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (11)
  • [10] Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC
    Ruiter, G.
    Tu, H. -Y.
    Ahn, M. -J.
    Yoh, K.
    Zugazagoitia, J.
    Smit, E.
    Wu, Y. -L.
    Planchard, D.
    Cho, B. -C.
    Wehler, B.
    Zhao, Y.
    von Wangenheim, U.
    Rohrbacher, M.
    Sadrolhefazi, B.
    Lin, G.
    Yu, Y.
    Nadal, E.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S4 - S5
123